Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Forecast, Price & News $51.88 -0.16 (-0.31%) (As of 12:20 PM ET) Add Compare Share Share Today's Range$49.54▼$51.9550-Day Range$49.50▼$66.6052-Week Range$43.00▼$69.06Volume86,372 shsAverage Volume243,832 shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$71.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunocore MarketRank™ ForecastAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside38.5% Upside$71.38 Price TargetShort InterestBearish6.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.40) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector575th out of 963 stocksBiological Products, Except Diagnostic Industry91st out of 160 stocks 4.5 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.38, Immunocore has a forecasted upside of 38.5% from its current price of $51.53.Amount of Analyst CoverageImmunocore has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.24% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 4.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 3.0 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immunocore this week, compared to 3 articles on an average week.Search Interest2 people have searched for IMCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Immunocore to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Immunocore is held by insiders.Percentage Held by Institutions73.45% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.40) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -39.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -39.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunocore (NASDAQ:IMCR) StockImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesSeptember 7, 2023 | marketbeat.comInstitutions are Buying These 3 Stocks and Analysts Agree (IMCR)Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.September 23, 2023 | americanbankingnews.comImmunocore (NASDAQ:IMCR) PT Raised to $85.00 at OppenheimerSeptember 25, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 22, 2023 | msn.comCardlytics, Immunocore See Activist ActionSeptember 22, 2023 | americanbankingnews.comImmunocore (NASDAQ:IMCR) Trading 2.8% Higher After Analyst UpgradeSeptember 18, 2023 | americanbankingnews.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 15, 2023 | americanbankingnews.comImmunocore (NASDAQ:IMCR) Upgraded at JPMorgan Chase & Co.September 15, 2023 | americanbankingnews.comImmunocore (NASDAQ:IMCR) Now Covered by Needham & Company LLCSeptember 25, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. September 13, 2023 | msn.comNeedham Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Buy RecommendationSeptember 13, 2023 | markets.businessinsider.comAnalyst Expectations for Immunocore Hldgs's FutureSeptember 13, 2023 | markets.businessinsider.comCancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst SaysAugust 23, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Immunocore Holdings (IMCR)August 16, 2023 | msn.comCapital One Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Overweight RecommendationAugust 13, 2023 | finance.yahoo.comImmunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | msn.comOppenheimer Maintains Immunocore Holdings plc - ADR (IMCR) Outperform RecommendationAugust 11, 2023 | msn.comBTIG Maintains Immunocore Holdings plc - ADR (IMCR) Buy RecommendationAugust 10, 2023 | finanznachrichten.deImmunocore Holdings Limited: Immunocore Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 10, 2023 | finance.yahoo.comImmunocore Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | benzinga.comImmunocore Hldgs's Earnings OutlookAugust 8, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Immunocore (IMCR)August 3, 2023 | finance.yahoo.comImmunocore to report second quarter 2023 financial results and host call on August 10, 2023July 18, 2023 | finance.yahoo.comImmunocore Holdings (NASDAQ:IMCR) shareholders have earned a 41% return over the last yearJuly 17, 2023 | msn.comCanaccord Genuity Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Hold RecommendationJune 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immunocore Holdings (IMCR)June 26, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Walgreens Boots Alliance (WBA) and Genmab (GMAB)June 20, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Buy Rating for Immunocore Holdings (IMCR)See More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Company Calendar Last Earnings8/10/2023Today9/25/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees408Year FoundedN/APrice Target and Rating Average Stock Price Forecast$71.38 High Stock Price Forecast$91.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+37.2%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,990,000.00 Net Margins-27.72% Pretax Margin-25.99% Return on Equity-17.97% Return on Assets-11.54% Debt Debt-to-Equity Ratio0.23 Current Ratio4.28 Quick Ratio4.26 Sales & Book Value Annual Sales$173.59 million Price / Sales14.67 Cash FlowN/A Price / Cash FlowN/A Book Value$7.17 per share Price / Book7.26Miscellaneous Outstanding Shares48,940,000Free Float46,151,000Market Cap$2.55 billion OptionableNot Optionable Beta0.67 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 61)CEO & Director Comp: $1.42MMr. Brian R. Di Donato M.B.A. (Age 56)CFO & Head of Strategy Ms. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchClayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGen. Counsel & Company Sec.Ms. Amy Judge-PreinChief Compliance OfficerMr. Sébastien DesprezHead of CommunicationsMs. Tina St. Leger (Age 55)Chief HR Officer & Director Dr. David Berman M.D. (Age 52)Ph.D., Head of R&D Ms. Debra NielsenChief of StaffMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTDenali TherapeuticsNASDAQ:DNLIBeam TherapeuticsNASDAQ:BEAMRecursion PharmaceuticalsNASDAQ:RXRXArcellxNASDAQ:ACLXView All CompetitorsInstitutional OwnershipBarclays PLCSold 5,843 shares on 9/21/2023Ownership: 0.403%Osaic Holdings Inc.Bought 1,197 shares on 8/21/2023Ownership: 0.004%HighVista Strategies LLCBought 30,900 shares on 8/15/2023Ownership: 0.092%Royal Bank of CanadaBought 23,705 shares on 8/15/2023Ownership: 0.049%Stifel Financial CorpBought 10,167 shares on 8/15/2023Ownership: 0.021%View All Institutional Transactions IMCR Stock - Frequently Asked Questions Should I buy or sell Immunocore stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks. What is Immunocore's stock price forecast for 2023? 13 Wall Street analysts have issued 1-year price targets for Immunocore's stock. Their IMCR share price forecasts range from $16.00 to $91.00. On average, they predict the company's stock price to reach $71.38 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts. How have IMCR shares performed in 2023? Immunocore's stock was trading at $57.07 at the beginning of the year. Since then, IMCR shares have decreased by 8.8% and is now trading at $52.04. View the best growth stocks for 2023 here. When is Immunocore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our IMCR earnings forecast. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The company earned $60.70 million during the quarter, compared to analyst estimates of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative trailing twelve-month return on equity of 17.97%. What ETFs hold Immunocore's stock? ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Range Cancer Therapeutics ETF (CNCR).BlackRock Future Health ETF (BMED). When did Immunocore IPO? (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO. What is Immunocore's stock symbol? Immunocore trades on the NASDAQ under the ticker symbol "IMCR." Who are Immunocore's major shareholders? Immunocore's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (6.30%), BlackRock Inc. (1.65%), Holocene Advisors LP (1.44%), Fiera Capital Corp (1.08%), Principal Financial Group Inc. (1.01%) and Braidwell LP (0.97%). How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunocore's stock price today? One share of IMCR stock can currently be purchased for approximately $52.04. How much money does Immunocore make? Immunocore (NASDAQ:IMCR) has a market capitalization of $2.55 billion and generates $173.59 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. How many employees does Immunocore have? The company employs 408 workers across the globe. How can I contact Immunocore? Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The official website for the company is www.immunocore.com. The company can be reached via phone at 44-12-3543-8600 or via email at ir@immunocore.com. This page (NASDAQ:IMCR) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.